Logo image of ATRA

ATARA BIOTHERAPEUTICS INC (ATRA) Stock Fundamental Analysis

NASDAQ:ATRA - Nasdaq - US0465132068 - Common Stock - Currency: USD

7.8  0 (0%)

After market: 7.88 +0.08 (+1.03%)

Fundamental Rating

2

ATRA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 560 industry peers in the Biotechnology industry. ATRA may be in some trouble as it scores bad on both profitability and health. ATRA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

ATRA had negative earnings in the past year.
ATRA had a negative operating cash flow in the past year.
In the past 5 years ATRA always reported negative net income.
In the past 5 years ATRA always reported negative operating cash flow.
ATRA Yearly Net Income VS EBIT VS OCF VS FCFATRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

ATRA has a Return On Assets of -25.21%. This is in the better half of the industry: ATRA outperforms 72.68% of its industry peers.
ATRA has a better Return On Invested Capital (4.91%) than 93.21% of its industry peers.
Industry RankSector Rank
ROA -25.21%
ROE N/A
ROIC 4.91%
ROA(3y)-101.92%
ROA(5y)-86.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ATRA Yearly ROA, ROE, ROICATRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600 -800

1.3 Margins

With an excellent Operating Margin value of 0.44%, ATRA belongs to the best of the industry, outperforming 91.43% of the companies in the same industry.
ATRA has a Gross Margin of 80.24%. This is amongst the best in the industry. ATRA outperforms 85.36% of its industry peers.
Industry RankSector Rank
OM 0.44%
PM (TTM) N/A
GM 80.24%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATRA Yearly Profit, Operating, Gross MarginsATRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

0

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ATRA is destroying value.
The number of shares outstanding for ATRA has been increased compared to 1 year ago.
Compared to 5 years ago, ATRA has less shares outstanding
ATRA has a worse debt/assets ratio than last year.
ATRA Yearly Shares OutstandingATRA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ATRA Yearly Total Debt VS Total AssetsATRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -42.37, we must say that ATRA is in the distress zone and has some risk of bankruptcy.
ATRA's Altman-Z score of -42.37 is on the low side compared to the rest of the industry. ATRA is outperformed by 92.14% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -42.37
ROIC/WACC0.64
WACC7.7%
ATRA Yearly LT Debt VS Equity VS FCFATRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 0.57 indicates that ATRA may have some problems paying its short term obligations.
With a Current ratio value of 0.57, ATRA is not doing good in the industry: 92.32% of the companies in the same industry are doing better.
A Quick Ratio of 0.57 indicates that ATRA may have some problems paying its short term obligations.
ATRA has a worse Quick ratio (0.57) than 92.32% of its industry peers.
Industry RankSector Rank
Current Ratio 0.57
Quick Ratio 0.57
ATRA Yearly Current Assets VS Current LiabilitesATRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

4

3. Growth

3.1 Past

ATRA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 93.01%, which is quite impressive.
The Revenue has grown by 475.45% in the past year. This is a very strong growth!
The Revenue has been growing by 85.07% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)93.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%160.87%
Revenue 1Y (TTM)475.45%
Revenue growth 3Y85.07%
Revenue growth 5YN/A
Sales Q2Q%258.77%

3.2 Future

The Earnings Per Share is expected to grow by 18.28% on average over the next years. This is quite good.
ATRA is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.92% yearly.
EPS Next Y60.52%
EPS Next 2Y29.66%
EPS Next 3Y20.69%
EPS Next 5Y18.28%
Revenue Next Year-70.2%
Revenue Next 2Y-47.57%
Revenue Next 3Y-40.72%
Revenue Next 5Y-0.92%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ATRA Yearly Revenue VS EstimatesATRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
ATRA Yearly EPS VS EstimatesATRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -50 -100

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ATRA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ATRA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATRA Price Earnings VS Forward Price EarningsATRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ATRA is valued cheaper than 95.89% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 12.65
ATRA Per share dataATRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20

4.3 Compensation for Growth

A more expensive valuation may be justified as ATRA's earnings are expected to grow with 20.69% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.66%
EPS Next 3Y20.69%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ATRA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ATARA BIOTHERAPEUTICS INC

NASDAQ:ATRA (5/30/2025, 8:00:01 PM)

After market: 7.88 +0.08 (+1.03%)

7.8

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2025-05-15/bmo
Earnings (Next)08-11 2025-08-11
Inst Owners51.62%
Inst Owner Change-77.26%
Ins Owners2.56%
Ins Owner Change1.14%
Market Cap52.18M
Analysts80
Price Target15.64 (100.51%)
Short Float %11.23%
Short Ratio9.91
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)170.35%
Min EPS beat(2)67.38%
Max EPS beat(2)273.33%
EPS beat(4)2
Avg EPS beat(4)49.39%
Min EPS beat(4)-94.51%
Max EPS beat(4)273.33%
EPS beat(8)5
Avg EPS beat(8)24.85%
EPS beat(12)6
Avg EPS beat(12)12.03%
EPS beat(16)8
Avg EPS beat(16)7.86%
Revenue beat(2)2
Avg Revenue beat(2)832.89%
Min Revenue beat(2)67.7%
Max Revenue beat(2)1598.08%
Revenue beat(4)3
Avg Revenue beat(4)412.01%
Min Revenue beat(4)-29.79%
Max Revenue beat(4)1598.08%
Revenue beat(8)4
Avg Revenue beat(8)182.71%
Revenue beat(12)5
Avg Revenue beat(12)157.39%
Revenue beat(16)7
Avg Revenue beat(16)118.04%
PT rev (1m)0%
PT rev (3m)15.72%
EPS NQ rev (1m)0%
EPS NQ rev (3m)60.82%
EPS NY rev (1m)0%
EPS NY rev (3m)45.17%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-37.38%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-62.13%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.26
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 12.65
EPS(TTM)-3.72
EYN/A
EPS(NY)-4.13
Fwd EYN/A
FCF(TTM)-10.07
FCFYN/A
OCF(TTM)-10.05
OCFYN/A
SpS29.86
BVpS-8.23
TBVpS-8.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.21%
ROE N/A
ROCE 6.22%
ROIC 4.91%
ROICexc 227.93%
ROICexgc 227.93%
OM 0.44%
PM (TTM) N/A
GM 80.24%
FCFM N/A
ROA(3y)-101.92%
ROA(5y)-86.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover3.22
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 6.42
Cap/Depr 2.18%
Cap/Sales 0.06%
Interest Coverage 1.38
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.57
Quick Ratio 0.57
Altman-Z -42.37
F-Score3
WACC7.7%
ROIC/WACC0.64
Cap/Depr(3y)34.79%
Cap/Depr(5y)54.33%
Cap/Sales(3y)7.02%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)93.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%160.87%
EPS Next Y60.52%
EPS Next 2Y29.66%
EPS Next 3Y20.69%
EPS Next 5Y18.28%
Revenue 1Y (TTM)475.45%
Revenue growth 3Y85.07%
Revenue growth 5YN/A
Sales Q2Q%258.77%
Revenue Next Year-70.2%
Revenue Next 2Y-47.57%
Revenue Next 3Y-40.72%
Revenue Next 5Y-0.92%
EBIT growth 1Y100.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year81.45%
EBIT Next 3Y12.47%
EBIT Next 5Y-3.99%
FCF growth 1Y70.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y70.03%
OCF growth 3YN/A
OCF growth 5YN/A